10 Best Cancer Stocks to Invest in for Long-Term Gains

8. Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Number of Hedge Fund Holders: 29

Total 5-Year Return: 691.21%

Celldex Therapeutics, Inc. (NASDAQ:CLDX) stands eighth on our list of the best cancer stocks. It is a biopharmaceutical company focused on developing innovative antibody-based therapies for cancer and inflammatory diseases. It creates monoclonal and bispecific antibodies to boost the immune system’s response.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is advancing its lead candidate, barzolvolimab, which is a first-in-class humanized monoclonal antibody targeting KIT, aimed at treating mast cell-driven disorders like chronic urticaria and eosinophilic esophagitis (EoE). Barzolvolimab is currently in Phase 3 trials for chronic spontaneous urticaria (CSU), with Phase 3 trials for chronic inducible urticaria (CIndU) expected in 2025. It’s also in Phase 2 for EoE, prurigo nodularis (PN), and atopic dermatitis (AD). Another pipeline asset, CDX-622, a bispecific antibody targeting SCF and TSLP, is in Phase 1 for inflammatory conditions. While the company is currently focused on inflammation, its antibody platform still holds oncology potential.

Financially, Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported $7 million in full-year 2024 revenue, flat year-over-year, with Q4 revenue at $1.2 million, down from $4.1 million due to fewer services provided to Rockefeller University. Their R&D expenses rose to $163.6 million in 2024, which reflected deeper investment in clinical programs. The net loss was $157.9 million, which was up from $141.4 million in 2023, consistent with late-stage biotech spending trends.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) also maintains a strong balance sheet with $725.3 million in cash and securities as of December 31, 2024—enough to fund operations through 2027. There is no reported debt, and Q4 cash burn was $32.5 million.

The company’s recent developments include the launch of the Phase 3 CIndU trial, pipeline expansion into atopic dermatitis, and the first-in-human trial for CDX-622.